Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Sarcoma × Ferrosoferric Oxide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Esophageal Neoplasms 2 Sarcoma 1 Colorectal Neoplasms 1 Childhood Brain Neoplasm 1

Interventions

Radiotherapy 5 Cyclophosphamide 4 pazopanib 3 Gemcitabine 3 Docetaxel 3 Biopsy 3 liposomal doxorubicin 2 Vincristine 2 Trastuzumab 2 Trabectedin 2 Temozolomide 2 Taxes 2 Surgical Procedures, Operative 2 Specimen Handling 2 Proton Therapy 2 Nivolumab 2 Ifosfamide 2 Filgrastim 2 Etoposide 2 Drug Therapy 2 Doxorubicin 2 Carboplatin 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 trastuzumab biosimilar HLX02 1 tozuleristide 1 tislelizumab 1 selinexor 1 regorafenib 1 pirarubicin 1 pidilizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01663090 2020-10-19

Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas

Dana-Farber Cancer Institute

Phase NA Withdrawn

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡